Jojima, T.; Wakamatsu, S.; Kase, M.; Iijima, T.; Maejima, Y.; Shimomura, K.; Kogai, T.; Tomaru, T.; Usui, I.; Aso, Y.
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2019, 20, 5237.
https://doi.org/10.3390/ijms20205237
AMA Style
Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, Kogai T, Tomaru T, Usui I, Aso Y.
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2019; 20(20):5237.
https://doi.org/10.3390/ijms20205237
Chicago/Turabian Style
Jojima, Teruo, Sho Wakamatsu, Masato Kase, Toshie Iijima, Yuko Maejima, Kenju Shimomura, Takahiko Kogai, Takuya Tomaru, Isao Usui, and Yoshimasa Aso.
2019. "The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma" International Journal of Molecular Sciences 20, no. 20: 5237.
https://doi.org/10.3390/ijms20205237
APA Style
Jojima, T., Wakamatsu, S., Kase, M., Iijima, T., Maejima, Y., Shimomura, K., Kogai, T., Tomaru, T., Usui, I., & Aso, Y.
(2019). The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 20(20), 5237.
https://doi.org/10.3390/ijms20205237